达格列净对2型糖尿病患者动脉内膜中层厚度的影响

doi:10.12092/j.issn.1009-2501.2018.07.015

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (7): 814-819.doi: 10.12092/j.issn.1009-2501.2018.07.015

达格列净对2型糖尿病患者动脉内膜中层厚度的影响

叶盛开¹，温洁¹，刘卫平²，任霞¹，陈海英¹，杜颖¹，李雪¹，张茹¹，于莉¹，张碧莹¹

¹解放军第210医院内分泌科，大连 116021，辽宁；²辽宁省军区大连第十三离职干部休养所，大连 116023，辽宁

收稿日期:2018-02-23 修回日期:2018-06-04 出版日期:2018-07-26 发布日期:2018-07-20
通讯作者: 温洁，女，硕士，主治医师，研究方向：内分泌及代谢性疾病。 Tel：0411-85841136 E-mail：wj_873@163.com
作者简介:叶盛开，男，硕士，副主任医师，研究方向：内分泌及代谢性疾病。 Tel：0411-85841197 E-mail：yeshengkai@163.com
基金资助:
中华社会救助基金会安心必达2型糖尿病公益项目（AXBD-Z-0001）

Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients

YE Shengkai ¹, WEN Jie ¹, LIU Weiping², REN Xia¹, CHEN Haiying¹, DU Ying 1, LI Xue ¹, ZHANG Ru ¹, YU Li ¹, ZHANG Biying ¹

¹Department of Endocrinology, the 210th Hospital of P.L.A, Dalian 116021, Liaoning, China; ²Dalian Thirteenth Rest Home of Liaoning Province Military Area, Dalian 116023,Liaoning,China

Received:2018-02-23 Revised:2018-06-04 Online:2018-07-26 Published:2018-07-20

摘要/Abstract

摘要：

目的: 探讨达格列净对2型糖尿病患者的动脉内膜中层厚度（intima-media thickness，IMT）的影响。方法: 113例2型糖尿病患者随机分为达格列净组（58 例）和对照组（55 例），均在生活方式干预的同时口服阿司匹林0.1 g/d及阿托伐他汀20 mg/d。达格列净组在上述治疗基础上每天服用达格列净10 mg，对照组加用其他类口服降糖药和(或)胰岛素治疗，总疗程24周，对2组患者分别进行各项生化指标及IMT的检测及比较。结果: 与治疗前相比，达格列净组治疗后IMT明显下降(P＜0.01)，对照组治疗前、后的IMT差异无统计学意义(P＞0.05)。治疗后2组间颈动脉IMT比较，差异有统计学意义（P＜0.01），而2组之间血糖及血压下降程度比较差异无统计学意义（P＞0.05）。结论: 达格列净能够降低2型糖尿病患者的IMT，考虑该药治疗2型糖尿病患者有一定的心血管获益与此有关。

关键词: 达格列净, 动脉内膜中层厚度, 2型糖尿病

Abstract:

AIM: To assess the effects of dapagliflozin on intima-medial thickness(IMT) of carotid artery in type 2 diabetic mellitus patients. METHODS: A total of 113 patients of type 2 diabetic mellitus were divided into dapagliflozin group (58 cases) and control group (55 cases).All patients were recruited in this randomized trial. Based on the intervention of life style，all patients undertook oral aspirin 0.1 g/d and atorvastatin 20 mg/d. The dapagliflozin group was given dapagliflozin 10 mg every day, while the control group was given other oral antidiabetic drug with/without insulin therapy. Course of treatment was 24 weeks. The various biochemical indices and carotid artery IMT were detected and the data were analyzed and compared between the two groups. RESULTS: In the dapagliflozin group, the IMT decreased after dapagliflozin therapy (P＜0.01).In the control group, the distinction of IMT had not statistical significant between before and after therapy (P＞0.05).There were significant differences in carotid artery IMT between the two groups after therapy (P＜0.01), while there was no statistically significant difference between decreased blood sugar and blood pressure level (P＞0.05). CONCLUSION: Dapagliflozin can decrease the IMT in patients with type 2 diabetic mellitus, which is closely related to cardiovascular benefit in patients with type 2 diabetic mellitus.

Key words: dapagliflozin, intima-media thickness, type 2 diabetes mellitus

中图分类号:

R587.1

叶盛开，温洁，刘卫平，任霞，陈海英，杜颖，李雪，张茹，于莉，张碧莹. 达格列净对2型糖尿病患者动脉内膜中层厚度的影响[J]. 中国临床药理学与治疗学, 2018, 23(7): 814-819.

YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.

参考文献

［1］刘川,马淑,杨伟.老年糖尿病合并冠心病患者血清抵抗素与代谢指标的相关性研究［J］.疑难病杂志,2016, 15(5):465-471.

［2］马红雨,董磊,孙立美,等. 维生素D与糖尿病肾病相关作用机制的研究进展［J］.空军医学杂志, 2017,33(4):283-285.

［3］Li MW. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013［J］.JAMA, 2017, 317(24):2515-2523.

［4］李盈盈,彭莉,毕晨超.体力活动对中老年2型糖尿病患者身体状况的影响［J］.保健医学研究与实践, 2017,14(4):105-107.

［5］刘畅,姜道利,刘小芳,等.链脲佐菌素诱导2型糖尿病大鼠合并脑缺血再灌注损伤模型优化方法的研究［J］.中国临床药理学与治疗学, 2017,22 (5):518-525.

［6］Ross R.The pathogenesis of atherosclerosis: a perspective for the 1990［J］. Nature,1993,362:8012-8021.

［7］史尔兰,李忠东,孙健,等.银杏叶提取物抑制人冠状动脉内皮细胞中的NF-κB表达及VAP-1、IL-6生成的研究［J］.空军医学杂志, 2016,32(4):242-245.

［8］Lee TM,Chang NC,Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts ［J］. Free Radic Biol & Med, 2017,104:298-310.

［9］Mikhail K, Matthew AC, Matthew ZF, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs［J］. Circulation,2017,136:249-259.

［10］金启辉,鲍晓峰,谷卫.胱抑素C与早期2型糖尿病患者颈动脉内膜中层厚度的相关性［J］.中华内分泌代谢杂志,2012, 28(1):29-31.

［11］张梅,张运,高月花,等.颈动脉及股动脉内膜-中膜层厚度正常值的对比研究［J］.中国医学影像技术,2002, 18(1):32-34.

［12］盛励,黄新梅,徐炯,等. 2型糖尿病患者颈动脉内膜中层厚度与轻度认知功能障碍的关系［J］.临床内科杂志, 2017,34(4):239-241.

［13］Kasami R,Kaneto H,Katakami N,et al.Relationship between carotid intima-media thickness and the presence and extent of coronary stenosis in type2 diabetic patients with carotid atherosclerosis but without historyof coronary artery disease［J］.Diabetes Care,2011,34:468-470.

［14］郑霄,胡晓晟.瑞舒伐他汀对高血压伴颈动脉硬化的疗效及对外周巨噬细胞极化的影响［J］.中国临床药理学与治疗学, 2017,22 (9):1035-1039.

［15］曹亚英,孙可欣,项骁,等.2型糖尿病患者血糖控制与颈动脉内膜中层厚度的相关性研究［J］.中华疾病控制杂志,2016,20(7):647-652.

［16］蒋玲玲.2型糖尿病颈动脉内膜中层厚度的相关因素研究［J］.糖尿病新世界,2017,20(1):50-51.

［17］隋淼,张弢,杨晓辉,等. 老年2型糖尿病患者血尿酸水平与颈动脉硬化间的关系研究［J］.检验医学与临床,2017,14(3):413-415.

［18］Holman RR,Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial［J］. Lancet Diabetes Endocrinol,2017, 5(11):877-886.

［19］Polak JF, Pencina MJ, Pencina KM, et al. Carotid-wall intima-media thickness and cardiovascular events［J］. N Engl J Med,2011,365(3):213-221.

［20］Cefalu WT, Leiter LA, de Bruin TW,et al.Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension［J］.Diabetes Care,2015,38(7):1218-1227.

［21］Leiter LA, Cefalu WT, de Bruin TW,et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension［J］. J Am Geriatr, 2014, 62(7):1252-1262.

［22］Weber MA, Mansfield TA, Cain VA,et al.Blood pressure and glycaemic effects of dapagliflozin in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study［J］. Lancet Diabetes Endocrinol, 2016, 4(3):211-220.

［23］Ishibashi Y, Matsui T, Yamagishi S.Tofogliflozin, A highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation［J］. Horm Metab Res, 2016, 48(3):191-195.

［24］Wilding JP,Woo V,Soler NG,et al.Long-term efficacy ofdapagliflozin in patients with type 2 diabetes mellitus receivinghigh doses of insulin［J］.Ann Intern Med,2012,156(6):405-415.

［25］Kosiborod M, Lam CSP, Kohsaka S, et al.Lower cardiovascular risk associated with SGLT-2i in >400,000 patients: the CVD-REAL 2 study［J］. J Am Coll Cardiol (in press). DOI: 10.1016/j.jacc.2018.03.009.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[3]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[4]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[5]	张雪娇, 刘洁婷, 李鲁新, 陈培剑, 丁明璐, 孙梦伟, 初彦辉, 张珍. 达格列净对1型糖尿病小鼠心肌损伤的影响及机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 257-265.
[6]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[7]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[8]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[9]	杨胜, 王德国. 沙库巴曲缬沙坦联合达格列净治疗射血分数减低型心力衰竭疗效及对血清cTnⅠ、BNP水平的影响[J]. 中国临床药理学与治疗学, 2022, 27(9): 1010-1015.
[10]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[11]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[12]	曾晓凡, 许宜琪, 刘书, 吴茜, 李自保, 何俊俊, 金岳龙, 赵永莉, 何春玲, 高家林. 回顾性分析小剂量阿司匹林对2型糖尿病病人非致死性心梗和脑梗一级预防的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 665-671.
[13]	邵茜, 郁亚南, 黄钰涵, 王晓彤, 凌宏威, 吕冬梅, 王涛. 艾塞那肽降低2型糖尿病患者体重的预测因素研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 287-294.
[14]	代红雨, 杨坤, 胡如春, 周红梅, 马佩敏, 郝倩. 0.25%罗哌卡因用于糖尿病患者坐骨神经阻滞的时效研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1278-1284.
[15]	陈倩, 王亚峰, 朵德龙, 常亚娥, 严英俊, 段坤坤. 琥珀酸曲格列汀对2型糖尿病小鼠肠道菌群的改变[J]. 中国临床药理学与治疗学, 2022, 27(1): 15-24.

达格列净对2型糖尿病患者动脉内膜中层厚度的影响

Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价